H.C. Wainwright analyst Robert Burns reiterated a Buy rating on PMV Pharmaceuticals today and set a price target of $5.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Robert Burns has given his Buy rating due to a combination of factors surrounding PMV Pharmaceuticals’ recent developments. The updated data from the Phase 2 PYNNACLE trial for rezatapopt in ovarian cancer shows promising results, with a 46% overall response rate in the ovarian cancer cohort, which is competitive with other treatments like Elahere and relacorilant. This positions rezatapopt as a strong candidate for a New Drug Application filing, particularly given the challenging prognosis for TP53 Y220C-mutated ovarian cancer patients.
Furthermore, PMV Pharmaceuticals has outlined a clear plan to enroll additional patients and expects to submit an NDA by the end of the first quarter of 2027. This strategic approach, coupled with the promising trial data, supports the potential for significant advancements in treatment options for ovarian cancer. These factors contribute to the reiteration of the Buy rating and a 12-month price target of $5 per share.